Eli Lilly and Company has emerged as in the development and tirzepatide, a groundbreaking treatment for type 2 diabetes. Tirzepatide, a dual GIP and GLP-1 receptor agonist, showcases significant ability to improve glycemic control and reduce heart disease. The sophisticated synthesis of tirzepatide utilizes a series of carefully controlled proce… Read More